Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cavion Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 2 distinct examiners, which suggests that the company is managing multiple independent review processes simultaneously. The workload is also spread across a matching number of distinct art units, indicating that the patent applications cover different technical sub-sectors within the biotechnology field.
FETTEROLF, BRANDON J is the busiest examiner for the portfolio, currently holding 1 pending action. Since this busiest examiner pending count of 1 is lower than the total of 2 pending office actions, the prosecution is divided between the distinct examiners. This lack of concentration means that the company's patent outcomes are not determined by a single individual. Practitioners must adapt to the different styles of the distinct examiners involved to ensure consistent results across the portfolio. The presence of multiple distinct art units further suggests a need for specialized technical arguments tailored to each unit's specific standards.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FETTEROLF, BRANDON J | 1 | 52.0% | +17.4% |
| LEE, CHIHYI NMN | 1 | 33.7% | +60.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18563101 | METHOD OF TREATING ESSENTIAL TREMOR | FETTEROLF, BRANDON J | 14d |
| 17766113 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | LEE, CHIHYI NMN | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18563101 | METHOD OF TREATING ESSENTIAL TREMOR | FETTEROLF, BRANDON J | 1626 | §103DP | Final Rejection | 14d | Pending | Nov 21, 2023 |
| 17766113 | METHODS AND MATERIALS FOR TREATING NEUROTOXICITY | LEE, CHIHYI NMN | 1628 | §103Other | Final Rejection | — | Pending | Apr 01, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial